A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis

Journal of Neurochemistry

Volumn 89, Issue 5, 2004, Pages 1241-1251

  Offen, Daniel ^a   Gilgun Sherki, Yossi ^a   Barhum, Yael ^a   Benhar, Moran ^b   Grinberg, Leonid ^b   Reich, Reuven ^b   Melamed, Eldad ^a   Atlas, Daphne ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

AD4; Blood brain barrier; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Oxidative stress; Reactive oxygen species; Thiol antioxidants

Indexed keywords

ACETYLCYSTEINE DERIVATIVE; CHELATING AGENT; COPPER CHELATING AGENT; FREE RADICAL; GELATINASE B; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; N ACETYLCYSTEINAMIDE; REACTIVE OXYGEN METABOLITE; SCAVENGER; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; BLOOD BRAIN BARRIER; CATALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMYELINATION; DRUG PENETRATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; INFLAMMATION; MOLECULAR WEIGHT; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL LINE; CELL MEMBRANE PERMEABILITY; CHELATING AGENTS; COPPER; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ERYTHROCYTES; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C3H; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR WEIGHT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

ANIMALIA;

EID: 2642579050     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02428.x     Document Type: Article

References (45)

1. Adler V., Yin Z., Tew K. D. and Ronai Z. (1999) Role of redox potential and reactive oxygen species in stress signaling, Oncogene 18, 6104-6111.
2. Atlas D., Melamed E. and Offen D. (1999) Brain targeted low molecular weight hydrophobic antioxidant compounds. United States Patent.
3. Barreto J. C., Smith G. S., Strobel N. H., McQuillin P. A. and Miller T. A. (1995) Terephthalic acid: a dosimeter for the detection of hydroxyl radicals in vitro. Life Sci. 56, PL89-96.
4. Behl C., Davis J. B., Lesley R. and Schubert D. (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77, 817-827.
5. Benhar M., Dalyot I., Engelberg D. and Levitzki A. (2001) Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell Biol. 21, 6913-6926.
6. Bernard C. C., Leydon J. and Mackay I. R. (1976) T cell necessity in the pathogenesis of experimental autoimmune encephalomyelitis in mice. Eur J Immunol. 6, 655-660.
7. Beutler E. (1974) Red cell metabolism: a manual of Biochemical Methods, pp. 55-59. Grune & Stratton, New York.
8. Boulton T. G., Nye S. H., Robbins D. J., Ip N. Y., Radziejewska E., Morgenbesser S. D., DePinho R. A., Panayotatos N., Cobb M. H. and Yancopoulos G. D. (1991) ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663-675.
9. Butterfield D. A., Koppal T., Subramaniam R. and Yatin S. (1999) Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev. Neurosci. 10, 141-149.
10. Chemy R. A., Atwood C. S., Xilinas M. E. et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676.
11. Cuzner M. L., Gveric D., Strand C., Loughlin A. J., Paemen L., Opdenakker G. and Newcombe J. (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55, 1194-1204.
12. Davis R. J. (1993) The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268, 14553-14556.
13. Emerson M. R. and LeVine S. M. (2000) Heme oxygenase-1 and NADPH cytochrome P450 reductase expression in experimental allergic encephalomyelitis: an expanded view of the stress response. J. Neurochem, 75, 2555-2562.
14. Finkel T. and Holbrook N. J. (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408, 239-247.
15. Gijbels K., Masure S., Carton H. and Opdenakker G. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41, 29-34.
16. Gilgun-Sherki Y., Melamed E. and Offen D. (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40, 959-975.
17. Gilgun-Sherki Y., Rosenbaum Z., Melamed E. and Offen D. (2002) Antioxidant therapy in acute central nervous system injury: current state. Pharmacol. Rev. 54, 271-284.
18. Grinberg L. N., Rachmilewitz E. A. and Newmark H. (1994) Protective effects of rutin against hemoglobin oxidation. Biochem. Pharmacol. 48, 643-649.
19. Gu Z., Kaul M., Yan B., Kridel S. J., Cui J., Strongin A., Smith J. W., Liddington R. C. and Lipton S. A. (2002) S-Nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190.
20. Hewson A. K., Smith T., Leonard J. P. and Cuzner M. L. (1995) Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44, 345-349.
21. Hogg N. (2000) Biological chemistry and clinical potential of S-nitrosothiols. Free Radic. Biol. Med. 28, 1478-1486.
22. Johnson G. L. and Lapadat R. (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912.
23. Lehmann D., Karussis D., Misrachi-Koll R., Shezen E., Ovadia H. and Abramsky O. (1994) Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 50, 35-42.
24. Leppert D., Waubant E., Burk M. R., Oksenberg J. R. and Hauser S. L. (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40, 846-852.
25. Liedtke W., Cannella B., Mazzaccaro R. J., Clements J. M., Miller K. M., Wucherpfennig K. W., Gearing A. J. and Raine C. S. (1998) Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44, 35-46.
26. Lindberg R. L., De Groot C. J., Montagne L., Freitag P., van der Valk P., Kappos L. and Leppert D. (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124, 1743-1753.
27. Liu Y., Zhu B., Luo L., Li P., Paty D. W. and Cynader M. S. (2001) Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 12, 1841-1845.
28. Luna L. G. (1968) Manual of Histologic Staining Methods of Armed Forces, pp. 193-194. McGraw-Hill.
29. Marracci G. H., Jones R. E., McKeon G. P. and Bourdette D. N. (2002) Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol. 131, 104-114.
30. Mehindate K., Sahlas D. J., Frankel D., Mawal Y., Liberman A., Corcos J., Dion S. and Schipper H. M. (2001) Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J. Neurochem. 77, 1386-1395.
31. Mendel I., Katz A., Kozak N., Ben-Nun A. and Revel M. (1998) Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur J. Immunol. 28, 1727-1737.
32. Miller A. C. and Henderson B. W. (1986) Effect of DL-buthionine-S,R.-sulfoximine on the growth of EMT6 and RIF mouse tumors. J. Natl Cancer Inst. 77, 505-510.
33. Ohta Y., Shiraishi N., Nishikawa T. and Nishikimi M. (2000) Copper-catalyzed autoxidations of GSH and 1-ascorbic acid: mutual inhibition of the respective oxidations by their coexistence. Biochim. Biophys. Acta 1474, 378-382.
34. Opazo C., Huang X., Chemy R. A. et al. (2002) Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277, 40302-40308.
35. Raine C. S. (1984) Biology of disease: analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab. Invest. 50, 608-635.
36. Rothstein J. D. (1996) Therapeutic horizons for amyotrophic lateral sclerosis. Curr. Opin. Neurobiol. 6, 679-687.
37. Sen C. K. (1998) Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem. Pharmacol. 55, 1747-1758.
38. Stuve O., Dooley N. P., Uhm J. H., Antel J. P., Francis G. S., Williams G. and Yong V. W. (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40, 853-863.
39. Takahashi E. and Berk B. C. (1998) MAP kinases and vascular smooth muscle function. Acta Physiol. Scand. 164, 611-621.
40. Trapp B. D., Peterson J., Ransohoff R. M., Rudick R., Mork S. and Bo L. (1998) Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285.
41. Uhm J. H., Dooley N. P., Stuve O., Francis G. S., Duquette P., Antel J. P. and Yong V. W. (1999) Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann. Neurol. 46, 319-324.
42. Whitham R. H., Bourdette D. N., Hashim G. A., Hemdon R. M., Ilg R. C., Vandenbark A. A. and Offner H. (1991) Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 146, 101-107.
43. Yong V. W., Chabot S., Stuve O. and Williams G. (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51, 682-689.
44. Yong V. W., Power C., Forsyth P. and Edwards D. R. (2001) Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2, 502-511.
45. Zor T. and Selinger Z. (1996) Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal. Biochem. 236, 302-308.